
Topic
Orange Book
Patent/exclusivity records, therapeutic-equivalence codes, reference-listed drugs, and ANDA planning.

Generics· June 22, 2026 · 19 min read
By Ran Chen#Generics#FDA Approval#Orange Book

Generics· June 21, 2026 · 5 min read
Generic Contrast Media: Amneal's Iohexol CGT Exclusivity and Shortage Triage
By Ran Chen#Generics#Orange Book#Manufacturing Capacity

Generics· June 21, 2026 · 7 min read
Generic Liraglutide ANDAs: The Orange Book AP1 vs. AP2 Split
By Ran Chen#Generic Entry#FDA Approval#Market Access

Generics· June 21, 2026 · 10 min read
Generic Sandostatin LAR Depot: CGT Exclusivity, Supply Shocks, and Buy-and-Bill Economics
By Ran Chen#Generics#Orange Book#HCPCS Coding

Generics· June 20, 2026 · 10 min read
Discontinued RLDs and Reference Standards: Generic Developer Workflow
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 16, 2026 · 12 min read
Single-source transdermal patches in the Orange Book: 385 products, 43% no generic
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 14, 2026 · 10 min read
Single-source inhaled drugs in the Orange Book: 506 products, 65% no generic
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 14, 2026 · 11 min read
Single-source ophthalmic drops in the Orange Book: 67 molecules, 11% AB-substitutable
By Ran Chen#Orange Book#ANDA Approval#Generic Entry

Generics· June 13, 2026 · 17 min read
Orange Book TE codes: how to tell whether a generic can actually be substituted
By Ran Chen#Orange Book#ANDA Approval#Generics

Generics· June 11, 2026 · 10 min read
Orange Book therapeutic equivalence: 48K products, 55% single-source, AB dominates
By Ran Chen#ANDA Approval#Orange Book#Generic Entry